NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Sino Biological's Expanded Nipah Virus Research Reagents
TL;DR
Sino Biological's accelerated NiV research tools offer companies a competitive edge in developing first-to-market vaccines and treatments for this high-mortality pathogen.
Sino Biological provides high-purity NiV G and F proteins, N proteins from recent strains, and endotoxin-free versions to support systematic vaccine and diagnostic research.
Sino Biological's expanded NiV reagent portfolio empowers global researchers to develop life-saving vaccines and treatments, potentially reducing the virus's devastating 40-75% fatality rate.
Nipah virus, a WHO priority pathogen with no approved treatments, has prompted Sino Biological to fast-track development of novel research proteins for scientific breakthroughs.
Found this article helpful?
Share it with your network and spread the knowledge!
Sino Biological is expanding its portfolio of research reagents specifically for Nipah virus (NiV) research to support global vaccine and diagnostic development efforts.
Nipah virus is classified by WHO as a priority pathogen due to its high fatality rate (40-75%) and epidemic potential, with no approved vaccines or specific antiviral treatments currently available.
Sino Biological has launched high-purity NiV G and F proteins, is fast-tracking development of NiV N proteins and pre-fusion/post-fusion F trimer proteins, and offers ProPure™ endotoxin-free versions of NiV G and F proteins for vaccine research.
The new NiV N proteins are based on the most recently reported strains, offering improved sequence relevance compared to existing products that contain multiple mutations.
These reagents are designed for the global scientific community, particularly researchers working on vaccine discovery, diagnostic development, and therapeutic antibody screening for Nipah virus.
Recent reports of Nipah virus infections in West Bengal, India, have reignited global concern, prompting public health authorities to prioritize research into this pathogen.
ProPure™ versions are endotoxin-free (ET-free) and designed specifically for vaccine research applications where immunogen purity and endotoxin control are critical.
According to Dr. Rob Burgess, their mission is to provide the scientific community with the highest quality tools as rapidly as possible when emerging infectious diseases threaten global health.
Researchers can visit https://www.sinobiological.com/research/virus/nipah-virus and https://www.sinobiological.com/research/virus/niv-proteins-reagent for more information.
Contact Sino Biological, Inc. at gmo@sinobiological.cn or visit www.sinobiological.com for media inquiries or partnership opportunities.
Curated from NewMediaWire
